Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection

Harbarth, Stéphan Juergen; Von Dach, Elodie; Pagani, Léonardo; Macedo-Vinas, M; Huttner, Benedikt; Olearo, Flaminia; Emonet, Stéphane; Uckay, Ilker

doi:10.1093/jac/dku352

Scientific article

English

Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection

ContributorsHarbarth, Stéphan Juergen

; Von Dach, Elodie; Pagani, Léonardo; Macedo-Vinas, M; Huttner, Benedikt

; Olearo, Flaminia; Emonet, Stéphane

; Uckay, Ilker

Published inThe journal of antimicrobial chemotherapy, vol. 70, no. 1, p. 264-272

Publication date2015

Abstract

The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Résistance aux antibiotiques (866)

Citation (ISO format)

HARBARTH, Stéphan Juergen et al. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. In: The journal of antimicrobial chemotherapy, 2015, vol. 70, n° 1, p. 264–272. doi: 10.1093/jac/dku352

Article (Published version)

Identifiers

PID : unige:41695
DOI : 10.1093/jac/dku352
PMID : 25209610

Journal ISSN0305-7453

638views

0downloads

Creation16/09/2014 07:55:00

First validation16/09/2014 07:55:00

Update time13/10/2025 22:15:29

Status update08/10/2024 09:17:23

Last indexation11/12/2025 00:22:02

Archive ouverte UNIGE

Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection

The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.

Technical informations